OS Therapies to Showcase 2.5-Year OST-HER2 Survival Data and Hold Investor Meetings
OSTX•OS Therapies will present 2.5-year overall survival data from Phase 2b OST-HER2 trial at ASCO 2026 May 29–June 2. It will hold partnering and investor meetings at Jefferies in New York (June 2–4), join a BIO panel in San Diego (June 22–25) and present osteosarcoma data in Columbus (June 25–27).
1. ASCO 2026 Overall Survival Data Presentation
OS Therapies will present updated 2.5-year overall survival results from its Phase 2b OST-HER2 trial at the American Society of Clinical Oncology meeting in Chicago May 29–June 2, highlighting event-free survival and overall survival endpoints in recurrent, resected lung metastatic osteosarcoma.
2. Jefferies Global Healthcare Conference Meetings
At the Jefferies Global Healthcare Conference in New York June 2–4, OS Therapies will conduct partnering sessions with potential collaborators and hold select investor meetings to discuss its listeria-based immunotherapy pipeline and expected 2026 regulatory milestones.
3. BIO International Convention Panel Participation
During the BIO International Convention in San Diego June 22–25, company executives will join a panel titled “ADCs: How can we make bringing ADCs to market a faster, simpler, and more collaborative process?” and host additional partnering meetings to advance its tunable ADC platform.
4. MIB Agents Factor Osteosarcoma Conference Data Presentation
At the MIB Agents: Factor Osteosarcoma Conference in Columbus June 25–27, OS Therapies will present clinical and preclinical data on its osteosarcoma immunotherapy programs, including OST-HER2 outcomes and next-generation ADC and drug conjugate platforms.
